Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas

Molecular Cancer Therapeutics

Volumn 13, Issue 8, 2014, Pages 2062-2072

  Bai, Xue Li ^a   Zhang, Qi ^a   Ye, Long Yun ^a   Hu, Qi Da ^a   Fu, Qi Han ^a   Zhi, Xiao ^a   Su, Wei ^a   Su, Ri Ga ^a   Ma, Tao ^a   Chen, Wei ^a   Xie, Shang Zhi ^a   Chen, Cong Lin ^a   Liang, Ting Bo ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; LB 100; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; LB-100; PHOSPHOPROTEIN PHOSPHATASE 2; PIPERAZINE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER CHEMOTHERAPY; CAPILLARY DENSITY; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG PENETRATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CAPILLARY PERMEABILITY; CARCINOMA, HEPATOCELLULAR; CELL MEMBRANE PERMEABILITY; DRUG EFFECTS; DRUG SCREENING; IC50; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BICYCLO COMPOUNDS, HETEROCYCLIC; CAPILLARY PERMEABILITY; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CISPLATIN; DOXORUBICIN; DRUG SYNERGISM; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS, EXPERIMENTAL; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; PROTEIN PHOSPHATASE 2; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905644201     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0800     Document Type: Article

References (49)

1. Van Hoof C, Goris J. PP2A fulfills its promises as tumor suppressor: which subunits are important? Cancer Cell 2004;5:105-6. (Pubitemid 38283792)
2. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008;14:152-60.
3. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell 2007;130:51-62. (Pubitemid 47039258)
4. Suganuma M, Fujiki H, Suguri H, Yoshizawa S, Hirota M, Nakayasu M, et al. Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc Natl Acad Sci U S A 1988;85:1768-71. (Pubitemid 24315763)
5. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007;130:21-4. (Pubitemid 47031327)
6. Gwinn D, Sweet-Cordero EA. The phosphatase PP2A links glutamine to the tumor suppressor p53. Mol Cell 2013;50:157-8.
7. Reid MA, Wang WI, Rosales KR, Welliver MX, Pan M, Kong M. The B55alpha subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Mol Cell 2013;50:200-11.
8. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, Hahn WC. Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell 2004;5:127-36. (Pubitemid 38283799)
9. Arnold HK, Sears RC. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev 2008;27:147-58.
10. Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McCluskey A. Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorg Med Chem Lett 2004;14:1969-73. (Pubitemid 38410875)
11. Li W, Xie L, Chen Z, Zhu Y, Sun Y, Miao Y, et al. Cantharidin, a potent and selective PP2A inhibitor, induces an oxidative stress-independent growth inhibition of pancreatic cancer cells through G2/M cell-cycle arrest and apoptosis. Cancer Sci 2010;101:1226-33.
12. Liu D, Chen Z. The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem 2009;9:392-6.
13. McCluskey A, Bowyer MC, Collins E, Sim ATR, Sakoff JA, Baldwin ML. Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity. Bioorg Med Chem Lett 2000;10:1687-90. (Pubitemid 30495241)
14. Kalev P, Sablina AA. Protein phosphatase 2A as a potential target for anticancer therapy. Anticancer Agents Med Chem 2011;11:38-46.
15. Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R, et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A 2009;106:11697-702.
16. Zhang C, Peng Y, Wang F, Tan X, Liu N, Fan S, et al. A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma. Biomaterials 2010;31:9535-43.
17. Colombo M, Sangiovanni A. The European approach to hepatocellular carcinoma. Hepatogastroenterology 2002;49:12-6. (Pubitemid 34289478)
18. Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005;42:588-97. (Pubitemid 41233651)
19. Zhao J, Zhang X, Shi M, Xu H, Jin J, Ni H, et al. TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU. Hepatology 2006;44:205-15. (Pubitemid 44049153)
20. Lee TK, Castilho A, Cheung VC, Tang KH, Ma SNg IO. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011;53:160-70.
21. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
22. Duong FH, Dill MT, Matter MS, Makowska Z, Calabrese D, Dietsche T, et al. Protein phosphatase 2A promotes hepatocellular carcinogenesis in the diethylnitrosamine mouse model through inhibiton of p53. Carcinogenesis 2014;35:114-22.
23. Wang CC, Wu CH, Hsieh KJ, Yen KY, Yang LL. Cytotoxic effects of cantharidin on the growth of normal and carcinoma cells. Toxicology 2000;147:77-87. (Pubitemid 30386908)
24. Wei DP, Parsels L, Karnak D, Davis MA, Parsels JD, Zhao LL, et al. Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin Cancer Res 2013;19:4422-32.
25. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999;5:1418-23.
26. Zhang Q, Bai X, Chen W, Ma T, Hu Q, Liang C, et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 2013;34:962-73.
27. Le Guelte A, Galan-Moya EM, Dwyer J, Treps L, Kettler G, Hebda JK, et al. Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation. J Cell Sci 2012;125:4137-46.
28. Martiniova L, Lu J, Chiang J, Bernardo M, Lonser R, Zhuang Z, et al. Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. PLoS ONE 2011;6:e14678.
29. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156:361-81. (Pubitemid 30648785)
30. Corada M, Liao F, Lindgren M, Lampugnani MG, Breviario F, Frank R, et al. Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood 2001;97:1679-84. (Pubitemid 32217233)
31. Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol 2004;5:261-70. (Pubitemid 38480607)
32. Kurosawa M. Phosphorylation and dephosphorylation of protein in regulating cellular function. J Pharmacol Toxicol Methods 1994;31:135-9. (Pubitemid 24195215)
33. Wallach D, Kovalenko A. Phosphorylation and dephosphorylation of the RIG-I-like receptors: a safety latch on a fateful pathway. Immunity 2013;38:402-3.
34. Radivojac P, Baenziger PH, Kann MG, Mort ME, Hahn MW, Mooney SD. Gain and loss of phosphorylation sites in human cancer. Bioinformatics 2008;24:i241-7.
35. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 2005;23:94-101. (Pubitemid 41724631)
36. Inuzuka H, Tseng A, Gao D, Zhai B, Zhang Q, Shaik S, et al. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell 2010;18:147-59.
37. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455-64. (Pubitemid 41637985)
38. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009;9:28-39.
39. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 2010;52:88-95.
40. Boudreau RT, Conrad DM, Hoskin DW. Apoptosis induced by protein phosphatase 2A (PP2A) inhibition in T leukemia cells is negatively regulated by PP2A-associated p38 mitogen-activated protein kinase. Cell Signal 2007;19:139-51. (Pubitemid 44883367)
41. Li W, Chen Z, Zong Y, Gong F, Zhu Y, Lv J, et al. PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKalpha and sustained activation of the NF-kappaB pathway. Cancer Lett 2011;304:117-27.
42. Cirak Y, Varol U, Atmaca H, Kisim A, Sezgin C, Karabulut B, et al. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. BJU Int 2012;110:E1147-54.
43. Li W, Li DM, Chen K, Chen Z, Zong Y, Yin H, et al. Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the alpha-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study. BMC Cancer 2012;12:547.
44. Thiery JP, Blazsek I, Legras S, Marion S, Reynes M, Anjo A, et al. Hepatocellular carcinoma cell lines from diethylnitrosamine phenobarbital- treated rats. Characterization and sensitivity to endothall, a protein serine/threonine phosphatase-2A inhibitor. Hepatology 1999;29:1406-17.
45. Mumby M. The 3D structure of protein phosphatase 2A: new insights into a ubiquitous regulator of cell signaling. ACS Chem Biol 2007;2:99-103. (Pubitemid 47490230)
46. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
47. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
48. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
49. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 2002;1:1.